The immuno-oncology therapy developer has amassed at least $190m of overall funding following a series B round backed by Lilly Asia Ventures.

US-based immuno-oncology therapy developer Synthekine has raised $108m in a series B round featuring Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. The round was co-led by investment firm Deerfield Management and asset manager Janus Henderson Investors. RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.